Literature DB >> 1887556

Pharmacokinetics and pharmacodynamics of piroxicam in dogs.

E A Galbraith1, Q A McKellar.   

Abstract

Piroxicam was administered to beagle dogs intravenously and orally at a dose rate of 0.3 mg/kg bodyweight. It had an elimination half-life of 40.2 hours, a volume of distribution of 0.29 +/- 0.02 litres/kg and a body clearance rate of 0.066 litres/hour. When administered orally it was 100 per cent bioavailable and maximum plasma concentrations were achieved quickly (3.1 +/- 1.0 hours). Piroxicam inhibited the generation of thromboxane B2 in the blood of dogs by more than 70 per cent and more than 50 per cent inhibition was maintained in most animals for 48 hours.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887556     DOI: 10.1136/vr.128.24.561

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  4 in total

1.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

Review 2.  Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-09       Impact factor: 2.093

3.  Toxico-Neurological Effects of Piroxicam in Monogastric Animals.

Authors:  Saganuwan Alhaji Saganuwan; Orinya Agbaji Orinya
Journal:  J Exp Neurosci       Date:  2016-10-11

4.  Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.

Authors:  Mohamed Elbadawy; Tatsuya Usui; Takashi Mori; Ryouichi Tsunedomi; Shoichi Hazama; Rina Nabeta; Tsuyoshi Uchide; Ryuji Fukushima; Toshinori Yoshida; Makoto Shibutani; Takaharu Tanaka; Sosuke Masuda; Rena Okada; Ryo Ichikawa; Tsutomu Omatsu; Tetsuya Mizutani; Yukie Katayama; Shunsuke Noguchi; Satomi Iwai; Takayuki Nakagawa; Yuta Shinohara; Masahiro Kaneda; Hideyuki Yamawaki; Kazuaki Sasaki
Journal:  Cancer Sci       Date:  2019-07-23       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.